User menu

Design for an ipriflavone multicenter European fracture study

Bibliographic reference Reginster, Jacques ; Bufalino, L ; Christiansen, C ; Devogelaer, Jean-Pierre ; Gennari, C ; et. al. Design for an ipriflavone multicenter European fracture study.1996 World Congress on Osteoporosis (AMSTERDAM (Netherlands), May 18-23, 1996). In: Calcified Tissue International, Vol. 61, p. S28-S32 (1997)
Permanent URL http://hdl.handle.net/2078.1/62724
  1. Melton L. Joseph, Atkinson Elizabeth J., O'Fallon W. Michael, Wahner Heinz W., Riggs B. Lawrence, Long-term fracture prediction by bone mineral assessed at different skeletal sites, 10.1002/jbmr.5650081010
  2. Consensus Development Conference (1994) Am J Med 94: 646–650
  3. Black Dennis M., Cummings Steven R., Genant Harry K., Nevitt Michael C., Palermo Lisa, Browner Warren, Axial and appendicular bone density predict fractures in older women, 10.1002/jbmr.5650070607
  4. WHO Technical Report Series no. 843 (1994)
  5. ETTINGER BRUCE, Long-Term Estrogen Replacement Therapy Prevents Bone Loss and Fractures, 10.7326/0003-4819-102-3-319
  6. Grady Deborah, Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women, 10.7326/0003-4819-117-12-1016
  7. Lufkin Edward G., Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen, 10.7326/0003-4819-117-1-1
  8. Reginster Jean-Yves L., Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis, 10.1016/s0169-6009(08)80099-2
  9. Morita Ikuo, Sakaguchi Kouji, Kurachi Toshiaki, Murota Sei-itsu, Ipriflavone inhibits murine osteoclast formationIn Vitro, 10.1007/bf02180242
  10. Tsuda Masao, Kitazaki Tadashi, Ito Toshio, Fujita Takuo, The effect of ipriflavone (TC-80) on bone resorption in tissue culture, 10.1002/jbmr.5650010207
  11. Bonucci Ermanno, Ballanti Paola, Martelli Antonietta, Mereto Eugenio, Brambilla Giovanni, Bianco Paolo, Bufalino Lidia, Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats, 10.1007/bf00301628
  12. Yamazaki Iwao, Shino Akio, Shimizu Yasuyoshi, Tsukuda Ryoichi, Shirakawa Yoshihiro, Kinoshita Masako, Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats, 10.1016/0024-3205(86)90265-1
  13. Benvenuti Susanna, Tanini Annalisa, Frediani Uliana, Bianchi Sandro, Masi Laura, Casano Rosaria, Bufalino Lidia, Serio Mario, Brandi Maria Luisa, Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line, 10.1002/jbmr.5650060913
  14. Notoya Kohei, Tsukuda Ryoichi, Yoshida Keiji, Taketomi Shigehisa, Stimulatory effect of ipriflavone on formation of bone-like tissue in rat bone marrow stromal cell culture, 10.1007/bf02180244
  15. Cheng S. -L., Zhang S. -F., Nelson T. L., Warlow P. M., Civitelli R., Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites, 10.1007/bf00299315
  16. Civitelli R., Abbasi-Jarhomi S. H., Halstead L. R., Dimarogonas A., Ipriflavone improves bone density and biomechanical properties of adult male rat bones, 10.1007/bf00298613
  17. Ghezzo C., Civitelli R., Cadel S., Borelli G., Maiorino M., Bufalino L., Bongrani S., Ipriflavone does not alter bone apatite crystal structure in adult male rats, 10.1007/bf00369217
  18. Mazzuoli GF, Agnusdei D, Crepaldi G, Isaia GC, Ortolani S, Passeri M, Bufalino L, Gennari C (1996) Inhibitory effect of ipriflavone on vertebral bone mass loss in postmenopausal women. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC Delmas PD (eds) Proceedings of 1996 World Congress on Osteoporosis, Amsterdam, 18-23 May. Elsevier, Amsterdam, The Netherlands pp 281–284
  19. Adami S., Bufalino L., Cervetti R., Di Marco C., Di Munno O., Fantasia L., Isaia G. C., Serni U., Vecchiet L., Passeri M., Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years, 10.1007/bf01623686
  20. Valente M., Bufalino L., Castiglione G. N., D'Angelo R., Mancuso A., Galoppi P., Zichella L., Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass, 10.1007/bf00305522
  21. Passeri M, Biondi M, Costi D, Dall’Aglio E, Pedrazzoni M, Bufalino L, Castiglione GN, Abate G (1995) Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Mineral Electrolyte Metab 9:137–144
  22. Maugeri D., Panebianco P., Russo M.S., Motta M., Tropea S., Motta L., Garozzo C., Lomeo E., Barbagallo Sangiorgi G., Scuderi G., Carozzo M., Cantatore F.P., Perpignano G., Ferraraccio A., Ennas F., Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years, 10.1016/0167-4943(94)00571-0
  23. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82–91
  24. Gambacciani Marco, Spinetti Adriana, Piaggesi Laura, Cappagli Barbara, Taponeco Fabio, Manetti Pietro, Weiss Carlo, Teti Gian Carlo, Commare Paolo La, Facchini Virgilio, Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists, 10.1016/s0169-6009(08)80159-6
  25. Agnusdei D., Gennari C., Bufalino L., Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone, 10.1007/bf01626609
  26. Genant Harry K., Wu Chun Y., van Kuijk Cornelis, Nevitt Michael C., Vertebral fracture assessment using a semiquantitative technique, 10.1002/jbmr.5650080915
  27. Smith-Bindman Rebecca, Cummings Steven R., Steiger Peter, Genant Harry K., A comparison of morphometric definitions of vertebral fracture, 10.1002/jbmr.5650060106
  28. Wu C. Y., Li J., Jergas M., Genant H. K., Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures, 10.1007/bf01622258
  29. Hansen MA, Hassager C, Overgaard K, Marslew U, Riis BJ, Christiansen C (1990) Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine. J Nucl Med 31:1156–1162
  30. Gillings Dennis, Koch Gary, The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials, 10.1177/009286159102500311
  31. CPMP 22 DOC/FINAL/JAL/SAK (15.12.94). Note for Guidance, Bruxelles